No Detail Found!

Expression and Clinical Signi cance of ANXA1 and DICER1 in Myelodysplastic Syndromes

Author(s)
Wenqi Wu Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Chengyao Wan Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Qiongni Xie Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Xiaolin Liang Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Jing Wen Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Zhenfang Liu Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Abstract
Objective: To explore the expression status of ANXA1 and DICER1 and their clinical signi cance in myelodysplastic syndromes (MDS) patients. Study Design: A case control study. Place and Duration of StudyD:epartment of Hematology, The First A liated Hospital of Guangxi Medical University, Nanning, Guangxi, China, from January 2011 to June 2020. Methodology: Quantitative real-time uorescence PCR (qRT-PC)Rwas carried out to detect ANXA1 and DICER1 expression levels in the bone marrow from 49 MDS patients and 12 healthy volunteers as control. The correlation of the clinical parameters and ANXA1 or DICER1 expression was then analysed in MDS. Results: Compared with normal controls, the expression of bone marrow ANXA1 and DICER1 in MDS patients was signi cantly decreased, especially in patients with secondary acute myeloid leukemia (s-AML). Moreover, down-expression of ANXA1 had a great e ect on di erentiating s-AML subjects from MDS cases, and DICER1 expression showed good performance to screen MDS subjects from normal controls. ANXA1 expression was negatively correlated with clinical features of poor prognosis such as the percentage of bone marrow blasts, IPSS and WHO subtypes. Conclusions: Bone marrow ANXA1 may be a potential biomarker for the risk prediction of leukemia transformation in MDS. DICER1 may have diagnostic signi cance to MDS.
Publication Details
Page(s) 1291-1296
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 30, Issue: 12, Year: 2020

Request the full text from PASTIC

Keywords
DICER1, Myelodysplastic syndrome, ANXA1, Secondary acute myeloid leukemia
0

Citations

0

Downloads

118

Views